Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

C1 esterase inhibitor · Ruconest

Recombinant protein · Inhibitor of Plasma kallikrein (KLKB1), Complement C1r (C1R) and Complement C1s (C1S) · developed by Pharming Healthcare

Approved FDA, Jun 2017
PHAR Developer
5 Registered trials

What is C1 esterase inhibitor?

C1 esterase inhibitor [recombinant] is a recombinant form of the human C1 esterase inhibitor protein, which regulates the complement and contact systems. It is studied in hereditary angioedema and angioedema, and in confirmed coronavirus disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ruconest, rhC1INH, rhC1INH or pdC1INH
Drug type
Recombinant protein
Targets
Plasma kallikrein (KLKB1), Complement C1r (C1R), Complement C1s (C1S)
Mechanism
Inhibitor of Plasma kallikrein (KLKB1), Complement C1r (C1R) and Complement C1s (C1S)
Pathways
complement classical pathway, contact system / kallikrein-kinin pathway
Therapy area
Immunology
Developer
Pharming Healthcare Inc. (PHAR)
Also in trials of
HALO
FDA status
Approved as Ruconest (June 22, 2017), BLA125495 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 30, 2020). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01188564 Phase 3 Hereditary Angioedema Completed PHAR
NCT00225147 Phase 2/3 Hereditary Angioedema Completed PHAR
NCT04530136 Phase 2 Confirmed Coronavirus Disease Completed PHAR
NCT01426763 Phase 2 Hereditary Angioedema Completed HALO
NCT01397864 N/A Hereditary Angioedema Completed PHAR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Angioneurotic EdemaConfirmed Coronavirus DiseaseHereditary Angioedema

Other drugs acting on KLKB1 / C1R / C1S

More from Pharming Healthcare

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PHAR page.

Follow PHAR, the company behind C1 esterase inhibitor

See PHAR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PHAR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.